- Home
- SKY vs OABI Comparison
SKY vs OABI Comparison
Compare SKY & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKY
- OABI
- Stock Information
- Founded
- SKY 2010
- OABI 2012
- Country
- SKY United States
- OABI United States
- Employees
- SKY N/A
- OABI N/A
- Industry
- SKY Homebuilding
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- SKY Consumer Discretionary
- OABI Health Care
- Exchange
- SKY Nasdaq
- OABI Nasdaq
- Market Cap
- SKY N/A
- OABI 185.9M
- IPO Year
- SKY N/A
- OABI N/A
- Fundamental
- Price
- SKY $65.40
- OABI $1.27
- Analyst Decision
- SKY Hold
- OABI Strong Buy
- Analyst Count
- SKY 5
- OABI 3
- Target Price
- SKY $80.60
- OABI $7.00
- AVG Volume (30 Days)
- SKY 737.6K
- OABI 814.0K
- Earning Date
- SKY 05-27-2025
- OABI 05-08-2025
- Dividend Yield
- SKY N/A
- OABI N/A
- EPS Growth
- SKY 35.18
- OABI N/A
- EPS
- SKY 3.42
- OABI N/A
- Revenue
- SKY $2,483,448,000.00
- OABI $26,744,000.00
- Revenue This Year
- SKY $6.10
- OABI N/A
- Revenue Next Year
- SKY $8.65
- OABI $40.06
- P/E Ratio
- SKY $19.12
- OABI N/A
- Revenue Growth
- SKY 22.65
- OABI 27.07
- 52 Week Low
- SKY $64.45
- OABI $1.22
- 52 Week High
- SKY $116.49
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- SKY 20.56
- OABI 27.15
- Support Level
- SKY $64.45
- OABI $1.35
- Resistance Level
- SKY $91.61
- OABI $1.41
- Average True Range (ATR)
- SKY 2.79
- OABI 0.09
- MACD
- SKY -2.92
- OABI 0.00
- Stochastic Oscillator
- SKY 3.07
- OABI 12.20
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.